CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis

Po Yin Chu, Ken Walder, Duncan Horlock, David Williams, Erin Nelson, Melissa Byrne, Karin Jandeleit-Dahm, Paul Zimmet, David M. Kaye

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to determine the mechanism by which cardiac fibrosis develops and to specifically investigate the role of the CXCR4 axis in this process. Animals with type I diabetes (streptozotocin treated mice) or type II diabetes (Israeli Sand-rats) and controls were randomized to treatment with a CXCR4 antagonist, candesartan or vehicle control. Additional groups of mice also underwent bone marrow transplantation (GFP+ donor marrow) to investigate the potential role of bone marrow derived cell mobilization in the pathogenesis of cardiac fibrosis. Both type I and II models of diabetes were accompanied by the development of significant cardiac fibrosis. CXCR4 antagonism markedly reduced cardiac fibrosis in both models of diabetes, similar in magnitude to that seen with candesartan. In contrast to candesartan, the anti-fibrotic actions of CXCR4 antagonism occurred in a blood pressure independent manner. Whilst the induction of diabetes did not increase the overall myocardial burden of GFP+ cells, it was accompanied by an increase in GFP+ cells expressing the fibroblast marker alpha-smooth muscle actin and this was attenuated by CXCR4 antagonism. CXCR4 antagonism was also accompanied by increased levels of circulating regulatory T cells. Taken together the current data indicate that pharmacological inhibition of CXCR4 significantly reduces diabetes induced cardiac fibrosis, providing a potentially important therapeutic approach.

LanguageEnglish
Article numbere0133616
JournalPloS one
Volume10
Issue number7
DOIs
Publication statusPublished - 27 Jul 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chu, P. Y., Walder, K., Horlock, D., Williams, D., Nelson, E., Byrne, M., ... Kaye, D. M. (2015). CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis. PloS one, 10(7), [e0133616]. https://doi.org/10.1371/journal.pone.0133616
Chu, Po Yin ; Walder, Ken ; Horlock, Duncan ; Williams, David ; Nelson, Erin ; Byrne, Melissa ; Jandeleit-Dahm, Karin ; Zimmet, Paul ; Kaye, David M. / CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis. In: PloS one. 2015 ; Vol. 10, No. 7.
@article{a20eed8365ef4918915b4b3ca432d730,
title = "CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis",
abstract = "Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to determine the mechanism by which cardiac fibrosis develops and to specifically investigate the role of the CXCR4 axis in this process. Animals with type I diabetes (streptozotocin treated mice) or type II diabetes (Israeli Sand-rats) and controls were randomized to treatment with a CXCR4 antagonist, candesartan or vehicle control. Additional groups of mice also underwent bone marrow transplantation (GFP+ donor marrow) to investigate the potential role of bone marrow derived cell mobilization in the pathogenesis of cardiac fibrosis. Both type I and II models of diabetes were accompanied by the development of significant cardiac fibrosis. CXCR4 antagonism markedly reduced cardiac fibrosis in both models of diabetes, similar in magnitude to that seen with candesartan. In contrast to candesartan, the anti-fibrotic actions of CXCR4 antagonism occurred in a blood pressure independent manner. Whilst the induction of diabetes did not increase the overall myocardial burden of GFP+ cells, it was accompanied by an increase in GFP+ cells expressing the fibroblast marker alpha-smooth muscle actin and this was attenuated by CXCR4 antagonism. CXCR4 antagonism was also accompanied by increased levels of circulating regulatory T cells. Taken together the current data indicate that pharmacological inhibition of CXCR4 significantly reduces diabetes induced cardiac fibrosis, providing a potentially important therapeutic approach.",
author = "Chu, {Po Yin} and Ken Walder and Duncan Horlock and David Williams and Erin Nelson and Melissa Byrne and Karin Jandeleit-Dahm and Paul Zimmet and Kaye, {David M.}",
year = "2015",
month = "7",
day = "27",
doi = "10.1371/journal.pone.0133616",
language = "English",
volume = "10",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

Chu, PY, Walder, K, Horlock, D, Williams, D, Nelson, E, Byrne, M, Jandeleit-Dahm, K, Zimmet, P & Kaye, DM 2015, 'CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis', PloS one, vol. 10, no. 7, e0133616. https://doi.org/10.1371/journal.pone.0133616

CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis. / Chu, Po Yin; Walder, Ken; Horlock, Duncan; Williams, David; Nelson, Erin; Byrne, Melissa; Jandeleit-Dahm, Karin; Zimmet, Paul; Kaye, David M.

In: PloS one, Vol. 10, No. 7, e0133616, 27.07.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis

AU - Chu, Po Yin

AU - Walder, Ken

AU - Horlock, Duncan

AU - Williams, David

AU - Nelson, Erin

AU - Byrne, Melissa

AU - Jandeleit-Dahm, Karin

AU - Zimmet, Paul

AU - Kaye, David M.

PY - 2015/7/27

Y1 - 2015/7/27

N2 - Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to determine the mechanism by which cardiac fibrosis develops and to specifically investigate the role of the CXCR4 axis in this process. Animals with type I diabetes (streptozotocin treated mice) or type II diabetes (Israeli Sand-rats) and controls were randomized to treatment with a CXCR4 antagonist, candesartan or vehicle control. Additional groups of mice also underwent bone marrow transplantation (GFP+ donor marrow) to investigate the potential role of bone marrow derived cell mobilization in the pathogenesis of cardiac fibrosis. Both type I and II models of diabetes were accompanied by the development of significant cardiac fibrosis. CXCR4 antagonism markedly reduced cardiac fibrosis in both models of diabetes, similar in magnitude to that seen with candesartan. In contrast to candesartan, the anti-fibrotic actions of CXCR4 antagonism occurred in a blood pressure independent manner. Whilst the induction of diabetes did not increase the overall myocardial burden of GFP+ cells, it was accompanied by an increase in GFP+ cells expressing the fibroblast marker alpha-smooth muscle actin and this was attenuated by CXCR4 antagonism. CXCR4 antagonism was also accompanied by increased levels of circulating regulatory T cells. Taken together the current data indicate that pharmacological inhibition of CXCR4 significantly reduces diabetes induced cardiac fibrosis, providing a potentially important therapeutic approach.

AB - Heart failure (HF) is an increasingly recognized complication of diabetes. Cardiac fibrosis is an important causative mechanism of HF associated with diabetes. Recent data indicate that inflammation may be particularly important in the pathogenesis of cardiovascular fibrosis. We sought to determine the mechanism by which cardiac fibrosis develops and to specifically investigate the role of the CXCR4 axis in this process. Animals with type I diabetes (streptozotocin treated mice) or type II diabetes (Israeli Sand-rats) and controls were randomized to treatment with a CXCR4 antagonist, candesartan or vehicle control. Additional groups of mice also underwent bone marrow transplantation (GFP+ donor marrow) to investigate the potential role of bone marrow derived cell mobilization in the pathogenesis of cardiac fibrosis. Both type I and II models of diabetes were accompanied by the development of significant cardiac fibrosis. CXCR4 antagonism markedly reduced cardiac fibrosis in both models of diabetes, similar in magnitude to that seen with candesartan. In contrast to candesartan, the anti-fibrotic actions of CXCR4 antagonism occurred in a blood pressure independent manner. Whilst the induction of diabetes did not increase the overall myocardial burden of GFP+ cells, it was accompanied by an increase in GFP+ cells expressing the fibroblast marker alpha-smooth muscle actin and this was attenuated by CXCR4 antagonism. CXCR4 antagonism was also accompanied by increased levels of circulating regulatory T cells. Taken together the current data indicate that pharmacological inhibition of CXCR4 significantly reduces diabetes induced cardiac fibrosis, providing a potentially important therapeutic approach.

UR - http://www.scopus.com/inward/record.url?scp=84941902143&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0133616

DO - 10.1371/journal.pone.0133616

M3 - Article

VL - 10

JO - PLoS ONE

T2 - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 7

M1 - e0133616

ER -

Chu PY, Walder K, Horlock D, Williams D, Nelson E, Byrne M et al. CXCR4 antagonism attenuates the development of diabetic cardiac fibrosis. PloS one. 2015 Jul 27;10(7). e0133616. https://doi.org/10.1371/journal.pone.0133616